Abstract: Objective Our previous study identified Threonine , located in the second intracellular loop of the δ-opioid receptor (DOR), as the only consensus phosphorylation site for cyclin-dependent kinase 5 (Cdk5). The aim of this study was to assess the function of DOR phosphorylation by Cdk5 in complete Freund's adjuvant (CFA)-induced inflammatory pain and morphine tolerance. Methods Dorsal root ganglion (DRG) neurons of rats with CFA-induced inflammatory pain were acutely dissociated and the biotinylation method was used to explore the membrane localization of phosphorylated DOR at Thr-161 (pThr-161-DOR), and paw withdrawal latency was measured after intrathecal delivery of drugs or Tat-peptide, using a radiant heat stimulator in rats with CFA-induced inflammatory pain. Results Both the total amount and the surface localization of pThr-161-DOR were significantly enhanced in the ipsilateral DRG following CFA injection.
Introduction
Morphine and its three types of opioid receptors (μ, δ and κ) have confounded researchers for decades with their enigmatic mechanism of controlling pain with exceptional efficacy. However, morphine antinociceptive tolerance has largely limited its use. The mechanisms of morphine antinociceptive tolerance are poorly understood due to the complexity of the underlying pathways. Nonetheless, accumulating evidence suggested that the δ-opioid receptor (DOR) plays an important role in the development of this tolerance [1] [2] [3] [4] . DOR -/-mice have no morphine tolerance [4, 5] .
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A gene knock-out does not induce morphine tolerance [6] .
Besides, μ-opioid receptor (MOR)-DOR heterodimerization has been indicated to play an important role in tolerance development [7, 8] .
Cyclin-dependent kinase 5 (Cdk5) is a unique member of the cyclin-dependent kinase (CDK) family. The Cdk5/ p35 complex plays a pivotal role in the nervous system.
Furthermore, Cdk5 activity has recently been shown to potentiate morphine tolerance [9] . Our previous study identified with Thr-161 site phosphorylation significantly attenuates the development of morphine antinociceptive tolerance [10] .
In the clinic, treatment of patients with inflammatory pain includes opioids acting outside the central nervous system [11] . Here, we chose a rat model of complete Freund's adjuvant (CFA)-induced inflammatory pain, and assessed the roles of phosphorylation of DORs by Cdk5 in CFAinduced inflammatory pain and morphine tolerance. For intrathecal (i.t.) drug administration, i.t. cannulas were implanted following the method of Storkson et al. [12] .
Materials and methods

Experimental animals
Briefly, rats were anesthetized with 10% chloral hydrate (0.3 g/kg, i.p.). The dorsal skin was incised and the spinal column was exposed. The intraspinal space between lumbar vertebrae 4 and 5 (L4 and L5) was chosen as the site of insertion of the needle. Slight movements of the tail indicated proper insertion of the needle into the subarachnoid space. A PE-10 polyethylene catheter (4.0 cm) was implanted using the catheter-through-needle technique to reach the lumbar enlargement. The outer end of the catheter was plugged and fixed onto the skin on closure of the wound. The rats were housed individually after surgery and allowed 5-6 days for recovery before being tested.
Animals with neurological damage after catheter implantation were excluded. Nociceptive responses after i.t. injection or delivery of drugs were measured in a blinded manner.
Tat-peptide, deltorphin I and anti-DOR-phosphothreonine-161 antibody (pDOR-Thr-161) construction
The engineered Tat fusion-interefering peptide corresponding to the second intracellular loop of DOR (Tat-DOR-2L) (RKKRRQRRRVKALDFRTPAKAKL) and Tat-control (Tat-ctrl) (RKKRRQRRRRAAKVPKFLTLDKA) were synthesized and purified by the Chinese Peptide Co., Hangzhou, China. The mass and purity of the peptides were verified by HPLC. Peptides were dissolved in 0.9%
NaCl to a concentration of 1 μg/μL.
was synthesized by GL Biochem (Shanghai) Ltd. Deltorphin I was dissolved in 0.9% NaCl to a concentration of 10 μg/12 μL.
Anti-pDOR-Thr-161 antibody was custom-made by 21st Century Biochemicals (Marlboro, MA, USA)
as described in our previous paper [10] . Briefly, rabbits were immunized with the pDOR-Thr-161 peptide AcVKALDFR(pT)PAKAKLC-amide conjugated to keyhole limpet hemocyanin. Sera were obtained after five consecutive bleeds. 2.5 Assessment of hypersensitivity Thermal hypersensitivity was assessed in unrestrained rats according to a previous report [13] . Briefly, the animals were placed onto the surface of a 2-mm-thick covered glass and were allowed 20 min for acclimation to the environment before testing.
Western blot
Paw withdrawal latency (PWL) in response to radiant heat was recorded by a stimulator. The PWL was averaged over four trials at 5-min intervals. To prevent tissue injury, the cut-off time was set at 30 s. 
Acute morphine antinociceptive tolerance
Delivery of drugs to the DRG After 5-6 days of
recovery from surgery for placement of the intrathecal catheter, rats were subjected to i.t. injection of Tat-ctrl or Tat-DOR-2L. The basal PWL was measured, and rats were subjected to i.t. injection of the peptides. After injection through the catheter, the needle remained in situ for 2 min before being withdrawn. Thirty minutes later, 100 μL 25%
CFA was injected into the plantar surface of the left hindpaw. Nociceptive responses were again measured at 1 h, 2 h, 6 h, 1 day, and 3 days after CFA administration.
For the acute morphine tolerance test, the basal PWL was measured, and CFA was injected into the plantar surface of the left hindpaw. One day after injection of CFA, PWL was measured and rats were subjected to i.t. injection of Tat-ctrl or Tat-DOR-2L (3 μL). These drugs were injected slowly over 2 min. After injection through the catheter, the needle remained in situ for 2 min before being withdrawn. Thirty minutes after injection of drugs, acute morphine antinociceptive tolerance was induced.
Statistical analysis
All data are presented as mean ± SEM. Differences between groups were compared using the unpaired t-test. The criterion for statistical significance was P <0.05.
Results
Phosphorylated DOR at Thr-161 (pThr-161-DOR)
in DRG neurons increased after CFA injection Our previous study indicated that Cdk5 phosphorylates Thr-161
in the second loop of the DOR, and this phosphorylation contributes to Cdk5-mediated morphine antinociceptive tolerance [10] . In the present study, we aimed to study the functions of phosphorylation of the DOR by Cdk5 in CFAinduced inflammatory pain and morphine tolerance. Based on our previous results, CFA-induced inflammatory hypersensitivity reached a peak and showed good reproducibility in the repeated experiments at 1 day after CFA and was maintained for more than 1 week in the ipsilateral paw [14] .
Thus we first tested whether Thr-161-DOR could be phosphorylated at 1 day after CFA injection by using acutely dissociated DRG neurons from the ipsilateral inflammatory side. Western blot (Fig. 1A ) and surface biotinylation (Fig.   1B ) results showed that both the total amount and the surface-localized pThr-161-DOR increased 1 day after CFA injection compared to the naïve group (n = 4, P <0.05).
Together, these results indicate that the phosphorylation of Thr-161-DOR might be involved in CFA-induced hypersensitivity. Tat fusion-interfering peptide corresponding to the second intracellular loop of the DOR (Tat-DOR-2L), including the TPAK sequence [10] . To study the role of Tat-DOR-2L
Intrathecal delivery of
in CFA-induced hypersensitivity, the basal PWL of rats was measured after 5 days of recovery from surgery. Rats were pretreated with 3 μg Tat-DOR-2L or Tat-ctrl, and 30
min later with CFA. Nociceptive responses were measured at 1 h, 2 h, 6 h, 1 day, or 3 days after CFA administration.
Compared with Tat-ctrl, pretreatment with Tat-DOR-2L
enhanced the CFA-induced heat hypersensitivity, and the effect was maintained until 1 day after inflammation (Fig.   2) . These results indicate that phosphorylation of DOR at Thr-161 attenuates CFA-induced heat hypersensitivity.
It was reported that deltorphin I, an agonist of the DOR, induces DOR-mediated spinal analgesia [29] . Here, we confirmed this result (Fig. 3) . After 5-6 days of recovery from surgery for placement of the i.t. catheter, we measured the basal PWL, and then CFA was injected into the (Fig. 3A) . In addition, at 20 min after deltorphin I injection, Tat-DOR-2L inhibited DOR-mediated spinal analgesia, while Tat-ctrl did not (Fig. 3A, B) . We concluded that disruption of Thr-161-DOR phosphorylation specifically reduced DOR-mediated spinal analgesia. Taken together, the phosphorylation of Thr-161-DOR by Cdk5 was important for heat hypersensitivity, and inhibition of this phosphorylation enhanced CFA-induced inflammatory Preclinical studies have shown that selective DOR agonists increase antinociceptive potency during peripheral inflammatory hypersensitivity [15, 16] , although MOR agonists are particularly used in the management of inflammatory pain. DOR ligands also have less abuse potential than morphine, and reduced respiratory gastrointestinal impairments than those produced by MOR agonists [17, 18] . Thus, strategies that increase the antinociceptive potency of DORs are promising targets for inflammatory pain treatment. or capsaicin also promotes the trafficking of DORs to the plasma membrane [19] . Under conditions of inflammatory injury, the levels of DOR and MOR mRNA and protein are increased in the ipsilateral dorsal horn [20] [21] [22] [23] . Visceral inflammation also similarly increases the levels of DOR mRNA in the dorsal horn, but the levels of protein are not significantly increased [24] . In DOR mutants, the increased hypersensitivity response seems to occur in both early and late phases after formalin injection, however, in MOR mutants this only happens in the early phase with no effects in the late phase [25] . These results indicate that both [23, [26] [27] [28] [29] [30] [31] [32] . The present study provides evidence that phosphorylation of Thr-161-DOR attenuates CFA-induced heat hypersensitivity.
Phosphorylation of the DOR by protein kinases
modulates its function It is still unclear whether the adaptations in cellular signaling evoked by repeated morphine administration lead to the development of tolerance. Evidence shows that intrathecal administration of roscovitine, an inhibitor of Cdk5, has an antinociceptive effect, while co-administration of roscovitine and morphine enhances the antinociceptive effect of morphine in tolerant rats [33] .
Parkitna and Przewlocki also reported that when injections of morphine are preceded by i.t. administration of roscovitine, the development of tolerance to morphine analgesia is completely abolished. Besides, a single i.t. injection of roscovitine restores the analgesic effect of morphine in a dose-dependent manner in tolerant rats. These workers supposed that chronic morphine treatment activates a highly efficient pathway by means of which Cdk5 regulates glycogen synthase kinase 3b activity [34] . The DOR has been conclusively shown to be involved in morphine antinoci- [1] [2] [3] [4] 35] . Recently, our group reported that mutation of the DOR at Thr-161 impairs acute morphine antinociceptive tolerance in vivo, which might be regulated by Cdk5.
Our previous results indicate that Cdk5 promotes this tolerance by phosphorylating Thr-161 of the DOR, and inhibition of this phosphorylation might destroy the function of DORs by reducing their surface expression and the formation of DOR-MOR heterodimers [10] . In the present study, we found that the phosphorylation level of Thr-161-DOR increased both in DRG neurons and on the membrane surface during CFA-induced inflammatory pain. We supposed that Cdk5 might regulate the membrane trafficking of DORs through phosphorylation at Thr-161 to play a role in CFA-induced hypersensitivity.
As noted above, Cdk5 can phosphorylate Thr-161-DOR, and indeed, the phosphorylation of an opioid receptor is the first step in its activation during the processes of desensitization and trafficking. As a classical G-protein-coupled receptor (GPCR), the phosphorylation state of an opioid receptor can be divided into two parts: basal (constitutive) phosphorylation, and agonist-induced phosphorylation.
Desensitization of GPCR signaling involves agonist-mediated receptor phosphorylation, followed by the recruitment of arrestins and sequestration of the arrestin-bound receptors into agonist-inaccessible cellular compartments [36] . The enzymes activated by phosphorylated opioid receptors include second messenger-dependent protein kinases [protein kinase C (PKC), cyclic AMP-dependent protein kinase II (CaMKII)], and G-protein kinases (MAPKs), which play important roles in the regulation of opioid signal transduction [37] . But, the information about the kinases for phosphorylating and modulating DOR function is limited.
Hypothesis of the development of morphine antinociceptive tolerance Receptor trafficking is considered
to be a key process in the regulation of receptor signaling.
In order to study DOR internalization, Pradhan and Kieffer created knock-in mice expressing fluorescent DOR (DOReGFP) in place of the endogenous receptor. The results of the study showed that DOR-eGFP internalization is strongly correlated with receptor phosphorylation and uncoupling from G-proteins [38] . Chronic morphine treatment produces adaptive changes at the β-arrestin 1 level, which in turn attenuate the agonist-mediated desensitization and internalization of GPCRs [39] . Patwardhan et al. have shown that peripheral activation of primary afferent nociceptors with bradykinin [40] or trypsin [41] enhances both the targeting of DORs to the cell surface and receptor competence.
Gendron et al. found a similar effect on DOR trafficking in small DRG neurons following injection of capsaicin into rat hindpaw [42] . Constitutive receptor activity has been reported to increase in animals treated chronically with morphine. Translocation of DORs from intracellular compartments to neuronal plasma membranes is induced by chronic morphine treatment, and then increases the numbers of functional receptors [19] . Another hypothesis about the development of morphine antinociceptive tolerance is the heterodimerization of MORs and DORs [43] .
This idea is further supported by findings that MORs and
DORs are co-expressed in the DRG [44] [45] [46] and some dorsal horn neurons [47, 48] , suggesting that physical interactions between MORs and DORs are possible in vivo. Considerable evidence demonstrates the formation of heterodimers between MORs and DORs in vitro and in vivo [49] [50] [51] . The membrane density of DORs was shown to increase 72 h after the induction of inflammation, an effect abolished in MOR-knockout (KO) mice [52] . Intrathecal administration of the DOR-selective agonist deltorphin II fails to have antihyperalgesic effects in MOR-KO mice [53] . Here, we demonstrated that interference with the phosphorylation of DORs attenuated morphine tolerance, without affecting the antinociception.
Disruption of DOR phosphorylation can attenuate morphine tolerance during CFA-induced hypersensitivity, which may potentially have important clinical advantages. In the present study, we first confirmed that DORs, phosphorylated by Cdk5, were involved in CFA-induced inflammatory hypersensitivity and morphine tolerance.
However, the mechanisms controlling this process are still undefined. Admitting that the analgesic effects and involvement in morphine tolerance of DORs are directly related to the level of DORs at the membrane [10, 19, 54] , our results suggest the hypothesis that phosphorylation of DORs by Cdk5 is important for its trafficking and distribution. 
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